Safety of first trimester dydrogesterone on the screening test confirmed - speculative hypothesis negated

A recent publication for Obstetricians who use Nuchal translucency (NT) measurements to screen for conditions such as Down syndrome.

Use of dydrogesterone in the prophylaxis of threatened miscarriage and its use in early pregnancy

Use of dydrogesterone in the first trimester of pregnancy does not affect Nuchal translucency (NT) measurements, a sensitive marker in Down syndrome screening and accepted as a component of first-trimester screening tests....Recent Study

This prospective case-control study consisted of 53 pregnant women using oral dydrogesterone due to the threat of miscarriage for at least 2 weeks and without vaginal bleeding for the last 72 h at the time of enrolment for the first-trimester screening test at 11-14th weeks of gestation. The control group was composed of 54 healthy pregnant women.

The results showed that dydrogesterone use in the first-trimester does not affect first-trimester aneuploidy screening tests components NT, pregnancy-associated plasma protein-A (PAPP-A), and free beta-human chorionic gonadotropin (B-hCG) values.

Dydrogesterone can be safely used in pregnant women without affecting the development of their baby.